consumption-hospital-admissions-55.html
DANMAP 2015 3D
56 / 144
danmap 2015 56 antimicrobial
consumption
in humans 5. (17%), closely followed by
penicillins
with extended spectrum (16%).
penicillins
in general accounted for 51% of the total
consumption
.
cephalosporins
(15%) and fluoroquinolones (9%) were also still among the most commonly consumed anti- microbial agents in hospitals (figure 5.13). the proportional
consumption
of
cephalosporins
increased from 11% in 2014. it is important to note delivery problems for the following intravenously administered antimicrobials: meropenem, van- comycin, clarithromycin and mecillinam. whether the shortage of these drugs was a consequence of increasing
consumption
is not known, but may very well be the case. the following additional sales to hospitals were reported from wholesalers: 290 ddd for meropenem, 3,121 ddd for vancomycin, 316 ddd for clarithromycin and 958 ddd for mecillinam. these numbers were not included in the figures and tables since it is not known how much of the extra deliverances actually were consumed. the additional sales amount only for around 0.1% of the total
consumption
and thus hardly had any impact on the total amounts of antimicrobials consumed. however, when there is shortage of important antimicrobial classes, changes in
consumption
of the other classes might happen as well, especially in hospital departments. the shortage of both me- ropenem and mecillinam thus very likely caused consequential increases in the
consumption
of piperazillin with tazobactam and probably also in gentamicin and
cephalosporins
. these drugs are all important in the treatment of sepsis and compli- cated urinary tract infections, as are meropenem and mecil- linam. for vancomycin it is more difficult to estimate whether other antimicrobials might have been affected by the deliv- erance shortage, since alternatives in treatment very much depend on the infectious disease to be treated. for clarithro- table5.5
consumption
of antibacterial agents for systemic use in somatic hospitals (ddd/100 occupied bed-days), denmark atc group (a) therapeutic group year 1997 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 j01aa tetracyclines 0.34 0.39 0.63 0.78 1.04 1.09 1.18 1.58 1.52 1.73 1.86 j01ca
penicillins
with extended spectrum 11.21 13.00 13.42 13.96 15.37 14.61 14.41 14.90 15.06 16.40 17.01 j01ce beta-lactamase sensitive
penicillins
8.02 10.67 10.79 9.98 9.90 9.49 9.32 10.13 10.13 10.31 10.03 j01cf beta-lactamase resistant
penicillins
4.44 6.51 6.70 6.81 7.40 7.71 7.30 8.37 9.07 9.57 9.80 j01cr combinations of
penicillins
. incl. beta-lactamase inhibitors 0.03 1.83 2.95 4.00 5.65 7.13 8.51 12.00 13.64 16.04 17.80 j01db first-generation
cephalosporins
0.13 0.14 0.13 0.18 0.13 0.13 0.13 0.12 0.11 0.06 0.04 j01dc second-generation
cephalosporins
3.99 9.38 12.31 13.32 15.76 16.21 16.14 14.15 12.32 11.68 10.40 j01dd third-generation
cephalosporins
0.50 0.83 1.03 1.25 1.42 1.26 1.39 1.07 1.08 1.02 1.06 j01df monobactams 0.06 0.00 0.04 0.07 0.06 0.09 0.19 0.15 0.14 0.06 0.03 j01dh carbapenems 0.36 1.38 2.13 2.70 3.15 4.02 4.16 3.86 4.02 4.09 4.10 j01ea trimethoprim and derivatives 0.42 0.42 0.44 0.44 0.44 0.36 0.36 0.38 0.41 0.52 0.46 j01eb short-acting sulfonamides 1.29 0.75 0.34 0.35 0.35 0.33 0.25 0.20 0.20 0.18 0.15 j01ee combinations of sulfonamides and trimethoprim. incl. derivatives 0.44 2.12 1.52 1.95 2.28 3.04 4.11 3.33 4.21 4.70 5.04 j01fa macrolides 3.45 2.83 3.08 3.06 3.42 3.52 3.69 3.56 3.39 3.88 4.56 j01ff lincosamides 0.13 0.31 0.35 0.41 0.50 0.47 0.53 0.62 0.64 0.65 0.57 j01gb aminoglycosides 3.38 1.81 1.79 1.64 1.56 1.71 1.91 2.14 2.13 1.61 1.68 j01ma fluoroquinolones 1.46 6.74 8.16 9.53 10.71 10.44 10.70 10.02 9.77 9.88 9.30 j01xa glycopeptides 0.21 0.56 0.63 0.68 0.99 1.07 1.24 1.29 1.29 1.15 1.07 j01xb polymyxins 0.04 0.12 0.05 0.05 0.07 0.10 0.09 0.09 0.16 0.27 0.25 j01xc steroid antibacterials (fusidic acid) 0.25 0.28 0.28 0.26 0.31 0.34 0.27 0.23 0.22 0.23 0.16 j01xd imidazole derivatives 1.42 2.78 2.62 3.27 3.84 3.93 4.19 4.16 4.08 4.48 4.25 j01xe nitrofuran derivatives (nitrofurantoin) 0.37 0.29 0.28 0.29 0.36 0.31 0.33 0.34 0.38 0.36 0.32 j01xx05 methenamine 0.18 0.11 0.09 0.10 0.09 0.08 0.10 0.09 0.09 0.07 0.09 j01xx08 linezolid 0.00 0.20 0.16 0.21 0.22 0.22 0.32 0.32 0.35 0.34 0.43 j01xx09 daptomycin 0.00 0.00 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.04 p01ab01 metronidazole 2.13 2.20 2.43 2.91 2.99 3.12 2.89 2.70 2.48 2.05 a07aa09 vancomycin 2.11 2.19 2.43 2.93 2.96 3.12 2.93 2.75 2.55 0.47 j01 antibacterial agents for systemic use (total) 42.13 67.71 74.33 80.14 90.87 93.67 97.08 98.94 99.88 104.34 103.02 danmap 2015
dbd-observed-penicillins-57.html
